SLC25A1 encodes the mitochondrial citrate/malate antiporter, a critical transporter that exports citrate from the mitochondria to the cytosol in exchange for malate 1. The protein can also mediate exchange of citrate with other substrates including isocitrate, phosphoenolpyruvate, and cis-aconitate, operating through consecutive substrate transport with sequential binding and dissociation 1. In the cytoplasm, exported citrate serves as a precursor for acetyl-CoA synthesis by ATP citrate lyase (ACLY), supporting fatty acid and sterol synthesis, glycolysis regulation, and protein acetylation 1. SLC25A1 plays important roles in cancer metabolism, where oncogenic KRAS upregulates its expression via GLI1 to reprogram lipid metabolism in pancreatic cancer 2. The transporter also regulates ferroptosis susceptibility by maintaining cytosolic acetyl-CoA levels necessary for FSP1 acetylation and stability 1. Additionally, SLC25A1 supports DNMT3A-R882-mutant clonal hematopoiesis through enhanced oxidative phosphorylation 3. Disease associations include congenital myasthenic syndrome type 23, highlighting its importance in neuromuscular junction function 4. Therapeutic targeting of SLC25A1 shows promise in cancer treatment and prevention of clonal hematopoiesis progression 13.